Ocular Toxicities & Management of Other Adverse Events with ADC's

Description

Recorded Live: May 17, 2022

Moderator:
Floor Backes, MD
USA

Speaker & Presentation Information

Mechanism of ADCs
Goffried E. Konency, MD
USA

Mechanism of Ocular Toxicity
Mark Slabaugh, MD
USA

Supported in part by

Summary

Availability:

On-Demand

Cost:

FREE

Create Account

Recommended

Novel combinations for treatment of recurrent cervical cancer - Webinar

Join Drs. Bradley Monk and Wendel Naumann on August 23 as they provide an overview of novel treatment options for recurrent cervical cancer, discuss combination therapy, and review recently completed clinical trials.

FREE

Second-Line Treatment Options for Patients with Recurrent Cervical Cancer. Review of Current Treatment and Future Directions

FREE

Treatment Options for Platinum Resistant Ovarian Cancer

FREE

Genitourinary System for the Gynecologic Oncologist

FREE

Interactive Updates on Selected Topics in Gynecology Oncology - Ovarian

FREE

Redefining Platinum Sensitivity : Additional Treatment Considerations in a Changing Paradigm

FREE

Uterine Cancers in the Molecular Era: Changing Trends and Implications

FREE

Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications

FREE

Journal Club: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

FREE

Phase II PICCOLO Trial Results

Results of Phase II PICCOLO Trial are available. Dr. Angeles Alvarez Secord, PI of PICCOLO Trial, and Dr. Wendel Naumann discuss results of MIRV in Recurrent Platinum-Sensitive Ovarian Cancer with High Folate Receptor-Alpha Expression.

FREE